Arbutus Biopharma Corp(ABUS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | RUT | P/E | 5.37 | EPS (ttm) | 0.78 | Insider Own | 20.55% | Shs Outstand | 197.6M | Perf Week | 0.24% |
| Market Cap | 0.83B | Forward P/E | - | EPS next Y | -110.81% | Insider Trans | - | Shs Float | 157.4M | Perf Month | -7.68% |
| Enterprise Value | 0.75B | PEG | - | EPS next Q | -0.02 | Inst Own | 67.07% | Short Float | 15.61% | Perf Quarter | -3.44% |
| Income | 0.15B | P/S | 4.59 | EPS this Y | 535.29% | Inst Trans | -4.36% | Short Ratio | 5.1 | Perf Half Y | -2.55% |
| Sales | 0.18B | P/B | 3.22 | EPS next 5Y | - | ROA | 81.13% | Short Interest | 24.57M | Perf YTD | -12.47% |
| Book/sh | 1.31 | P/C | 9 | EPS past 3/5Y | 27.58% 29.45% | ROE | 89.58% | 52W High | -22.75% ($5.45) | Perf Year | -13.02% |
| Cash/sh | 0.47 | P/FCF | - | Sales past 3/5Y | -28.8% 15.29% | ROIC | 58.45% | 52W Low | 20.29% ($3.50) | Perf 3Y | 136.52% |
| Dividend Est. | - | EV/EBITDA | 5.05 | EPS Y/Y TTM | 376.44% | Gross Margin | 99.98% | Volatility(W/M) | 2.95% 3.95% | Perf 5Y | 4.47% |
| Dividend TTM | - | EV/Sales | 4.1 | Sales Y/Y TTM | 1078.78% | Oper. Margin | 81.13% | ATR (14) | 0.15 | Perf 10Y | 33.65% |
| Dividend Ex-Date | - | Quick Ratio | 81.42 | EPS Q/Q | -298.47% | Profit Margin | 84.23% | RSI (14) | 39.88 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 81.42 | Sales Q/Q | -90.56% | SMA20 | -1.23% ($4.26) | Beta | 0.82 | Target Price | $5.5 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/12 | SMA50 | -10.68% ($4.71) | Rel Volume | 0.52 | Prev Close | $4.28 |
| Employees | 19 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -50% 44.86% | SMA200 | -6.36% ($4.5) | Avg Volume(3M) | 4.82M | Price | $4.21 |
| IPO | 2007/7/23 | Option/Short | Yes/Yes | Trades | 8363 | Volume | 2,524,825 | Change | -1.64% |
🧬 Arbutus Biopharma is a clinical-stage biotech company with the goal of curing chronic hepatitis B, trading under the ticker ABUS. It pursues a functional cure by combining an RNAi-based foundational drug with an oral immunomodulator, and leverages its deep virology expertise as a core competitive advantage.
Over the past 1 year, roughly in the middle
23% below its 1-year high.
Traded less than usual. That is 52% of its average volume.
ABUS makes money exceptionally well
Of every $100 in sales, $81.13 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +535.3% this year.
Tap to view numbers
Within its industry, it looks cheap
For a company earning $100 a year, you would pay $537. Peers typically go for $749.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are roughly flat
Bought 5 years ago, your return today would be +4.5%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 67.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #174 of 597 in the industry
Based on market cap of $834M.
IVA#170 Inventiva ADR $868M PER - 
PHAR#171 Pharming Group NV ADR $866M PER 38.8 
PRME#172 Prime Medicine Inc $856M PER - 
CRVS#173 Corvus Pharmaceuticals Inc $844M PER - ABUS#174 Arbutus Biopharma Corp $834M PER 5.4 
FAQ
What kind of company is ABUS?
ABUS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ABUS?
The market cap of ABUS is approximately $834M, ranking 2,722 within its sector.
What is the P/E ratio of ABUS?
ABUS has a P/E ratio of approximately 5.4x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ABUS?
ABUS has recorded a 52-week high of $5.45 and a low of $3.50.
